A Kunjin Replicon Virus-like Particle Vaccine Provides Protection Against Ebola Virus Infection in Nonhuman Primates

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2015 Mar 4

PMID 25732811

Citations 20

Authors

Oleg V Pyankov

Sergey A Bodnev

Olga G Pyankova

Vladislav V Solodkyi

Stepan A Pyankov

Yin Xiang Setoh

Valentina A Volchkova

Andreas Suhrbier

Viktor V Volchkov

Alexander A Agafonov

Alexander A Khromykh

Affiliations

Soon will be listed here.

Abstract

The current unprecedented outbreak of Ebola virus (EBOV) disease in West Africa has demonstrated the urgent need for a vaccine. Here, we describe the evaluation of an EBOV vaccine candidate based on Kunjin replicon virus-like particles (KUN VLPs) encoding EBOV glycoprotein with a D637L mutation (GP/D637L) in nonhuman primates. Four African green monkeys (Cercopithecus aethiops) were injected subcutaneously with a dose of 10(9) KUN VLPs per animal twice with an interval of 4 weeks, and animals were challenged 3 weeks later intramuscularly with 600 plaque-forming units of Zaire EBOV. Three animals were completely protected against EBOV challenge, while one vaccinated animal and the control animal died from infection. We suggest that KUN VLPs encoding GP/D637L represent a viable EBOV vaccine candidate.

Citing Articles

Tracing down the updates on Ebola virus surges: An update on anti-ebola therapeutic strategies.

Malik S, Waheed Y J Transl Int Med. 2023; 11(3):216-225.

PMID: 37662888 PMC: 10474883. DOI: 10.2478/jtim-2023-0100.

mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV.

Matarazzo L, Bettencourt P Front Immunol. 2023; 14:1172691.

PMID: 37168860 PMC: 10166207. DOI: 10.3389/fimmu.2023.1172691.

Replication-Deficient Zika Vector-Based Vaccine Provides Maternal and Fetal Protection in Mouse Model.

Garcia Jr G, Chakravarty N, Abu A, Jeyachandran A, Takano K, Brown R Microbiol Spectr. 2022; 10(5):e0113722.

PMID: 36169338 PMC: 9602260. DOI: 10.1128/spectrum.01137-22.

The Delivery of mRNA Vaccines for Therapeutics.

Nitika , Wei J, Hui A Life (Basel). 2022; 12(8).

PMID: 36013433 PMC: 9410089. DOI: 10.3390/life12081254.

A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses.

Oreshkova N, Myeni S, Mishra N, Albulescu I, Dalebout T, Snijder E Vaccines (Basel). 2021; 9(12).

PMID: 34960238 PMC: 8704410. DOI: 10.3390/vaccines9121492.

References

Harvey T, Liu W, Wang X, Linedale R, Jacobs M, Davidson A . Tetracycline-inducible packaging cell line for production of flavivirus replicon particles. J Virol. 2003; 78(1):531-8. PMC: 303381. DOI: 10.1128/jvi.78.1.531-538.2004. View

Dolnik O, Volchkova V, Garten W, Carbonnelle C, Becker S, Kahnt J . Ectodomain shedding of the glycoprotein GP of Ebola virus. EMBO J. 2004; 23(10):2175-84. PMC: 424403. DOI: 10.1038/sj.emboj.7600219. View

Davis K, Anderson A, Geisbert T, Steele K, Geisbert J, Vogel P . Pathology of experimental Ebola virus infection in African green monkeys. Involvement of fibroblastic reticular cells. Arch Pathol Lab Med. 1997; 121(8):805-19. View

Ksiazek T, West C, Rollin P, Jahrling P, Peters C . ELISA for the detection of antibodies to Ebola viruses. J Infect Dis. 1999; 179 Suppl 1:S192-8. DOI: 10.1086/514313. View

Pijlman G, Suhrbier A, Khromykh A . Kunjin virus replicons: an RNA-based, non-cytopathic viral vector system for protein production, vaccine and gene therapy applications. Expert Opin Biol Ther. 2006; 6(2):135-45. DOI: 10.1517/14712598.6.2.135. View

Geisbert T, Daddario-DiCaprio K, Williams K, Geisbert J, Leung A, Feldmann F . Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol. 2008; 82(11):5664-8. PMC: 2395203. DOI: 10.1128/JVI.00456-08. View

Kanapathipillai R, Restrepo A, Fast P, Wood D, Dye C, Kieny M . Ebola vaccine--an urgent international priority. N Engl J Med. 2014; 371(24):2249-51. DOI: 10.1056/NEJMp1412166. View

Reynard O, Mokhonov V, Mokhonova E, Leung J, Page A, Mateo M . Kunjin virus replicon-based vaccines expressing Ebola virus glycoprotein GP protect the guinea pig against lethal Ebola virus infection. J Infect Dis. 2011; 204 Suppl 3:S1060-5. PMC: 3189994. DOI: 10.1093/infdis/jir347. View

Geisbert T, Feldmann H . Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis. 2011; 204 Suppl 3:S1075-81. PMC: 3218670. DOI: 10.1093/infdis/jir349. View

10.

Herbert A, Kuehne A, Barth J, Ortiz R, Nichols D, Zak S . Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus. J Virol. 2013; 87(9):4952-64. PMC: 3624300. DOI: 10.1128/JVI.03361-12. View

11.

Smith L, Hensley L, Geisbert T, Johnson J, Stossel A, Honko A . Interferon-β therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J Infect Dis. 2012; 208(2):310-8. PMC: 3685222. DOI: 10.1093/infdis/jis921. View

12.

Marzi A, Feldmann H . Ebola virus vaccines: an overview of current approaches. Expert Rev Vaccines. 2014; 13(4):521-31. PMC: 4785864. DOI: 10.1586/14760584.2014.885841. View

13.

Stanley D, Honko A, Asiedu C, Trefry J, Lau-Kilby A, Johnson J . Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med. 2014; 20(10):1126-9. DOI: 10.1038/nm.3702. View

14.

Geisbert T, Geisbert J, Leung A, Daddario-DiCaprio K, Hensley L, Grolla A . Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol. 2009; 83(14):7296-304. PMC: 2704787. DOI: 10.1128/JVI.00561-09. View